Amundi Pioneer Asset Management Inc. decreased its position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 57.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 127,878 shares of the medical technology company’s stock after selling 174,264 shares during the period. Amundi Pioneer Asset Management Inc. owned about 0.19% of Hill-Rom worth $11,324,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. Securian Asset Management Inc grew its holdings in shares of Hill-Rom by 1.2% during the 4th quarter. Securian Asset Management Inc now owns 8,231 shares of the medical technology company’s stock worth $729,000 after acquiring an additional 100 shares during the period. Mastrapasqua Asset Management Inc. grew its holdings in shares of Hill-Rom by 0.7% during the 4th quarter. Mastrapasqua Asset Management Inc. now owns 14,830 shares of the medical technology company’s stock worth $1,313,000 after acquiring an additional 105 shares during the period. Johanson Financial Advisors Inc. grew its holdings in shares of Hill-Rom by 4.8% during the 4th quarter. Johanson Financial Advisors Inc. now owns 2,437 shares of the medical technology company’s stock worth $217,000 after acquiring an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Hill-Rom by 4.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,400 shares of the medical technology company’s stock worth $390,000 after acquiring an additional 189 shares during the period. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of Hill-Rom by 1.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 21,482 shares of the medical technology company’s stock worth $1,902,000 after acquiring an additional 271 shares during the period. Hedge funds and other institutional investors own 85.15% of the company’s stock.
A number of research analysts have weighed in on the company. Barclays upped their target price on Hill-Rom from $103.00 to $108.00 and gave the stock an “equal weight” rating in a report on Monday, April 15th. ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research cut Hill-Rom from a “hold” rating to a “sell” rating in a research report on Friday, March 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $116.00 price target on shares of Hill-Rom in a research report on Monday, March 11th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $109.88.
Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, January 25th. The medical technology company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.04. The business had revenue of $683.50 million for the quarter, compared to analysts’ expectations of $676.39 million. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.92 EPS. On average, equities analysts anticipate that Hill-Rom Holdings, Inc. will post 5.04 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 22nd were given a $0.21 dividend. The ex-dividend date of this dividend was Thursday, March 21st. This is a boost from Hill-Rom’s previous quarterly dividend of $0.20. This represents a $0.84 annualized dividend and a yield of 0.88%. Hill-Rom’s dividend payout ratio is 17.68%.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: What are the benefits of momentum investing?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.